A Phase 1/2 interventional study of ICP-723 in Advanced Solid Tumors Harboring NTRK Fusion and Primary Central Nervous System Tumors Harboring NTRK Fusion, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Central Nervous System Neoplasms with a site in China — 4 open to participants now, 7 under way, none of them phase 3. Central Nervous System Neoplasms · China.
Among the 11 studies in Central Nervous System Neoplasms with a site in China, this one is one of 3 that started in 2022, is one of 4 in phase 1/2, and was the 9th registered.
699 studies on the registry are indexed under Central Nervous System Neoplasms; 65 are open to participants now.
Browse Central Nervous System Neoplasms studies →4 of the 11 studies in Central Nervous System Neoplasms with a site in China are open now. Recruiting first, the newest first:
Ming Yang · Sites in China
Beijing Tiantan Hospital · Sites in China
Ages 0–18
Suzhou Maximum Bio-tech Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 56 Central Nervous System Neoplasms studies recruiting now, 34 (61%) set no upper age limit and 19 (34%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5
First in 2008; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 35 across 487 interventional studies indexed under Central Nervous System Neoplasms.
Median enrollment 56 across the 8 interventional studies, 1,000 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing InnoCare Pharma Tech Co., Ltd., one of the names counted as InnoCare Pharma Limited. Under that name alone:
Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.
InnoCare Pharma Limited has 1 study filed under Central Nervous System Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Central Nervous System Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT05599984AbbVieStudy to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Central Nervous System Neoplasms with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ICP-723
ICP-723 tablet administered orally,once a day,for every 28 days as one cycle
Objective response rate (ORR)
The objective response rate (ORR) evaluated by the Independent Center Review
Time frame: Through study completion, an average of 4 years
ORR assessed by the investigator
Time frame: Through study completion, an average of 4 years
DCR as assessed by the investigator and the IRC
Time frame: Through study completion, an average of 4 years
Time to response (TTR) as assessed by the investigator and the IRC
Time frame: Through study completion, an average of 4 years
Duration of response (DOR) as assessed by the investigator and the IRC
Time frame: Through study completion, an average of 4 years
Progression-free survival (PFS) as assessed by the investigator and the IRC
Time frame: Through study completion, an average of 4 years
Intracranial objective response rate (IC-ORR) as assessed by the investigator and IRC
Time frame: Through study completion, an average of 4 years
central nervous system progression-free survival (CNS-PFS) as assessed by the investigator and IRC
Time frame: Through study completion, an average of 4 years
Overall survival (OS)
Time frame: Through study completion, an average of 4 years
The incidence, character and severity of adverse events as assessed per NCI-CTCAE v5.0 criteria
Time frame: Through study completion, an average of 4 years
The maximum plasma concentration observed (Cmax)
Time frame: Through study completion, an average of 4 years
Time of maximum observed plasma concentration (Tmax)
Time frame: Through study completion, an average of 4 years
Elimination half-life (t1/2)
Time frame: Through study completion, an average of 4 years
AUC0-∞
Time frame: Through study completion, an average of 4 years
AUC0-t
Time frame: Through study completion, an average of 4 years
Apparent clearance (CL/F)
Time frame: Through study completion, an average of 4 years
Apparent volume of distribution (Vz/F)
Time frame: Through study completion, an average of 4 years
Colony-stimulating factor (CSF) concentrations
Time frame: Through study completion, an average of 4 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.
Of 35 phase 1/2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 85. This study's planned 59 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zurletrectinib
Central Nervous System Neoplasms →
Beijing InnoCare Pharma Tech Co., Ltd. →